TG Therapeutics jumps after strong Q2 beat and guidance raise

TG Therapeutics (NASDAQ:TGTX) shares rose ~16% in the premarket on Wednesday after the biotech well exceeded expectations with its Q2 2024 financials and once again raised its full-year sales outlook for its multiple sclerosis therapy, Briumvi.

The Morrisville, North Carolina-based biotech said